ELF1 and prostate cancer: To test this hypothesis, chromatin immunoprecipitation coupled with next-generation sequencing (ChIP-seq) was used to map ELF1 genomic binding in RWPE-1 and PC3 cells and compared to a published ChIP-seq of ELF1 in DU145 prostate cancer cells [36].